文献速递泌尿男性生殖肿瘤

多学科膀胱癌门诊背景下根治性膀胱切除术与保留膀胱三联治疗的倾向性评分分析

Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
PubMed 文献 · J Clin Oncol · 2017-04-14

本研究在多学科膀胱癌门诊(MDBCC)中回顾性分析2008至2013年肌层浸润性膀胱癌(MIBC)患者,采用倾向性评分匹配比较根治性膀胱切除术(RC)与保留膀胱三联治疗(TMT)的肿瘤学结局。匹配后共纳入112例患者(RC组56例,TMT组56例),中位随访4.51年,两组5年疾病特异性生存(DSS)率分别为73.2%和76.6%(P=0.49),差异无统计学意义。作者认为,在多学科门诊背景下,TMT的生存结局与匹配的RC患者相似,经过适当选择的MIBC患者应有机会讨论包括保留器官TMT在内的各种治疗选择。

要点

  • 匹配后RC组与TMT组各56例,5年DSS率分别为73.2%和76.6%(P=0.49),差异无统计学意义。
  • TMT组56例中6例(10.7%)接受了挽救性膀胱切除术。
  • 作者认为,在多学科门诊背景下,经过适当选择的MIBC患者应有机会讨论包括保留器官TMT在内的各种治疗选择。

核心结论

  • 在多学科膀胱癌门诊背景下,TMT的生存结局与匹配的RC患者相似。
  • 经过适当选择的MIBC患者应有机会讨论包括保留器官TMT在内的各种治疗选择。

研究设计与样本

  • 回顾性分析2008至2013年在多学科膀胱癌门诊(MDBCC)治疗的患者数据。
  • 采用倾向性评分匹配,按性别、cT和cN分期、东部肿瘤协作组(ECOG)状态、Charlson合并症评分、治疗日期、年龄、原位癌状态和肾积水状态,将接受TMT的MIBC患者与接受RC的患者进行匹配。
  • 匹配后共纳入112例MIBC患者,其中TMT组56例,RC组56例。
  • 采用Cox比例风险模型评估总生存,采用竞争风险分析评估疾病特异性生存(DSS)。

主要发现

  • 匹配后患者中位年龄为68.0岁,29.5%为cT3/cT4期疾病。
  • 中位随访4.51年,RC组死亡20例(35.7%),其中13例死于膀胱癌;TMT组死亡22例(39.3%),其中13例死于膀胱癌。
  • RC组和TMT组的5年DSS率分别为73.2%和76.6%(P=0.49)。
  • TMT组56例患者中6例(10.7%)接受了挽救性膀胱切除术。

临床怎么用

  • 作者认为,在多学科膀胱癌门诊背景下,经过适当选择的MIBC患者应有机会讨论包括保留器官TMT在内的各种治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Multidisciplinary management improves complex treatment decision making in cancer care, but its impact for bladder cancer (BC) has not been documented. Although radical cystectomy (RC) currently is viewed as the standard of care for muscle-invasive bladder cancer (MIBC), radiotherapy-based, bladder-sparing trimodal therapy (TMT) that combines transurethral resection of bladder tumor, chemotherapy for radiation sensitization, and external beam radiotherapy has emerged as a valid treatment option. In the absence of randomized studies, this study compared the oncologic outcomes between patients treated with RC or TMT by using a propensity score matched-cohort analysis. Methods Data from patients treated in a multidisciplinary bladder cancer clinic (MDBCC) from 2008 to 2013 were reviewed retrospectively. Those who received TMT for MIBC were identified and matched (for sex, cT and cN stage, Eastern Cooperative Oncology Group status, Charlson comorbidity score, treatment date, age, carcinoma in situ status, and hydronephrosis) with propensity scores to patients who underwent RC. Overall survival and disease-specific survival (DSS) were assessed with Cox proportional hazards modeling and a competing risk analysis, respectively. Results A total of 112 patients with MIBC were included after matching (56 who had been treated with TMT, and 56 who underwent RC). The median age was 68.0 years, and 29.5% had stage cT3/cT4 disease. At a median follow-up of 4.51 years, there were 20 deaths (35.7%) in the RC group (13 as a result of BC) and 22 deaths (39.3%) in the TMT group (13 as a result of BC). The 5-year DSS rate was 73.2% and 76.6% in the RC and TMT groups, respectively ( P = .49). Salvage cystectomy was performed in 6 (10.7%) of 56 patients who received TMT. Conclusion In the setting of a MDBCC, TMT yielded survival outcomes similar to those of matched patients who underwent RC. Appropriately selected patients with MIBC should be offered the opportunity to discuss various treatment options, including organ-sparing TMT.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kulkarni GS, Hermanns T, Wei Y, et al. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. J Clin Oncol. 2017. PMID: 28410011. doi:10.1200/JCO.2016.69.2327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。